Hepion Pharmaceuticals stock gets 750 million share authorization

Published on 10/07/2026 at 01:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hepion Pharmaceuticals stock was trading at USD 0.12 on October 6, 2026, up 20 percent. A secured note carries a 12,500,000-share warrant and 8 percent interest.

HEPA, US4268974015, Illustration mit AI erstellt.

Hepion Pharmaceuticals stock (ISIN US4268974015) was trading at USD 0.12 on the OTCQB on October 6, 2026 at 3:31 p.m. ET, up 20 percent from the prior session. The latest corporate action expanded the company’s authorized common shares to 750,000,000.

Share authorization reaches 750 million

According to StockTitan, the amendment to Hepion's Certificate of Incorporation became effective on October 1, 2026. The filing identifies HEPA as an OTC QB security and lists 750,000,000 authorized common shares.

That figure represents a sixfold increase from the 120,000,000 authorized shares described in Hepion's September 2026 definitive information statement, while the same filing cited 98,220,476 common shares outstanding as of August 31, 2026, according to StockTitan.

Financing adds dilution risk

The expanded authorization also matters because Hepion disclosed a financing structure that can increase the share count. The September 3, 2026 transaction included a USD 500,000 secured convertible note and a warrant for 12,500,000 shares, as reported in the company's filing by StockTitan.

The note bears 8 percent annual interest payable in kind, converts at USD 0.04 per share after the required approval, and matures on September 3, 2027. The warrant carries a USD 0.06 exercise price and expires on September 3, 2031, while the note is secured by all company assets.

Price reaches the yearly high

HEPA's USD 0.12 price on October 6, 2026 matched its 52-week high and stood USD 0.09 above its USD 0.03 low. The session volume was 8,757 shares, and the market capitalization was USD 1.4 million as of the same date.

Hepion describes its business as early cancer detection using liquid biopsy diagnostics, including a methylated DNA biomarker test and a circulating tumor RNA assay, on its investor relations page. MarketBeat lists October 14, 2026 as the next earnings report date.

HEPA stock trades at USD 0.12

Hepion Pharmaceuticals stock was last at USD 0.12 on the OTCQB on October 6, 2026 at 3:31 p.m. ET, with a 20 percent daily gain and a market capitalization of USD 1.4 million.